Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sumatriptan
Drug ID BADD_D02098
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00451
MeSH ID D018170
PubChem ID 5358
TTD Drug ID D0Z6UC
NDC Product Code 80425-0258; 52932-0733; 42043-220; 65145-118; 72189-404; 62331-048; 42043-222; 55150-173; 55700-969; 63629-8701; 0173-0737; 55700-918; 70069-804; 0527-1859; 63304-097; 69452-344; 0480-2014; 45802-619; 0173-0736; 0245-0812; 60429-995; 63304-098; 63304-099; 53873-058; 67835-5011; 0173-0479; 0173-0524; 66993-084; 0527-1818; 36000-289; 66993-082; 69452-345; 69452-346; 71921-170; 58437-017; 0143-9638; 0173-0523; 63187-164; 63187-323; 63629-8703; 69097-644; 80425-0318; 50370-0029; 53873-057; 58437-016; 58437-018; 0173-0735; 53002-3562; 66993-083; 80425-0224; 53873-059; 42043-221; 0173-0478; 66993-081; 68071-2825; 0480-2013; 45802-598; 0173-0739
UNII 8R78F6L9VO
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C14H21N3O2S
CAS Registry Number 103628-46-2
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Optic ischaemic neuropathy24.04.10.001; 17.04.05.006; 06.07.03.001--Not Available
Osteoarthritis15.01.04.001--Not Available
Otitis externa11.01.05.003; 04.01.02.001--
Overdose12.11.01.002--Not Available
Pain08.01.08.004--
Pain in jaw15.02.01.003--Not Available
Pain of skin23.03.03.003--
Pallor08.01.03.032; 24.03.04.001; 23.03.03.031--Not Available
Palpitations02.11.04.0120.000312%
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Panic disorder19.06.04.002--Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.000367%
Paralysis17.01.04.004--Not Available
Parkinsonism17.01.05.003--Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Peptic ulcer07.04.07.001--Not Available
Peripheral ischaemia24.04.03.002--
Personality change17.02.05.019; 19.05.01.006--
Pharyngeal haemorrhage24.07.02.017; 22.04.05.002--
Phlebitis24.12.03.004; 12.02.01.002--
Phobia19.06.03.002--Not Available
Photophobia06.01.01.004; 17.17.02.0060.000122%
Photopsia17.17.01.006; 06.02.06.004--
Photosensitivity reaction23.03.09.003--
Pituitary tumour16.24.01.003; 05.03.05.002--Not Available
Pollakiuria20.02.02.007--
Polydipsia14.05.02.001; 05.03.03.002--Not Available
Pregnancy18.08.02.004--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene